Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027
Pfizer is addressing patent cliff concerns with 32% revenue growth from new and acquired drugs in Q3 2026. Despite investor pessimism reflected in a 6.1% dividend yield, the company maintains financial strength with $1.8B in cash and $12.4B in short-term investments. Management is committed to maintaining and growing its dividend, supported by strong cash flow metrics.